Diligence memo · auto-generated · as of July 2, 2026
Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Allena Pharmaceuticals, Inc. operates in Pharmaceuticals, based in NEWTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Allena Pharmaceuticals, Inc. has raised $80M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $51M on 2015-11-25.
Most recent recorded round closed around 2022-05-04.
Valuation (modeled)modeled
Provath models Allena Pharmaceuticals, Inc. at approximately $75M (range $13M–$154M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.13× the median modeled value of Series C Pharmaceuticals companies in 2022–2024 (30 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 45 months.
Last raise 4.2 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 12.7× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 89% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 50% of those peers.
Closest niche peers: Vigil Neuroscience, Inc., Leap Therapeutics, Inc., Alimera Sciences Inc, VYNE Therapeutics Inc., Lusaris Therapeutics, Inc..
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.